Alector, Inc. (NASDAQ:ALEC – Get Free Report) has earned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.00.
A number of brokerages have commented on ALEC. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research report on Thursday, June 20th. HC Wainwright reaffirmed a “buy” rating and set a $35.00 target price on shares of Alector in a report on Thursday, June 20th.
Read Our Latest Stock Report on ALEC
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in ALEC. Gladius Capital Management LP bought a new stake in shares of Alector during the 2nd quarter valued at about $29,000. Allspring Global Investments Holdings LLC bought a new stake in Alector during the 1st quarter valued at approximately $40,000. Lazard Asset Management LLC purchased a new position in shares of Alector during the 1st quarter worth approximately $59,000. China Universal Asset Management Co. Ltd. raised its position in shares of Alector by 352.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,733 shares of the company’s stock worth $78,000 after acquiring an additional 7,584 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new position in shares of Alector in the 4th quarter valued at approximately $81,000. 85.83% of the stock is currently owned by institutional investors.
Alector Price Performance
Shares of NASDAQ:ALEC opened at $6.49 on Monday. The company’s fifty day moving average price is $5.02 and its 200-day moving average price is $5.71. The firm has a market capitalization of $625.57 million, a price-to-earnings ratio of -4.70 and a beta of 0.73. Alector has a one year low of $3.66 and a one year high of $9.06.
Alector (NASDAQ:ALEC – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.10. Alector had a negative return on equity of 71.80% and a negative net margin of 125.11%. The business had revenue of $15.89 million for the quarter, compared to analysts’ expectations of $14.63 million. As a group, equities research analysts expect that Alector will post -1.93 EPS for the current year.
Alector Company Profile
Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.
Featured Articles
- Five stocks we like better than Alector
- 3 Ways To Invest In Coffee, Other Than Drinking It
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- High Flyers: 3 Natural Gas Stocks for March 2022
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Alector Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alector and related companies with MarketBeat.com's FREE daily email newsletter.